Related Experiment Video
Updated: Jan 16, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
The Hidden Dangers: Superabsorbent Polymer Beads as a Cause of Bowel Obstruction in Children
SaraPettey Sandifer1, Alicia C Greene2, Quincy Erturk1
1The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Insights
Superabsorbent polymer (SAP) bead ingestion can cause dangerous bowel obstruction in children. In vitro studies show hyperosmolar agents and osmotic laxatives can shrink these beads, potentially avoiding surgery.
Area of Science:
- Pediatric Surgery
- Gastroenterology
- Materials Science
Background:
- Superabsorbent polymer (SAP) bead ingestion is a significant risk for children, often leading to bowel obstruction.
- Surgical intervention is frequently required for SAP bead-induced intestinal blockages.
Purpose of the Study:
- To review existing literature on pediatric SAP bead ingestion and bowel obstruction.
- To investigate in vitro strategies for contracting enlarged SAP beads to potentially prevent surgery.
Main Methods:
- Conducted a literature review of SAP bead ingestion cases in children.
- Performed an in vitro experiment using SAP beads in a simulated intestinal environment.
- Tested various hyperosmolar agents and osmotic laxatives for their bead size reduction efficacy.
Main Results:
- Identified 87 pediatric cases of SAP bead-induced bowel obstruction, with ultrasound being more effective for diagnosis than radiography.
- 85.6% of patients required surgical enterotomy, and reoperations were common.
- In vitro, GoLYTELY reduced SAP bead size by 35.17% within 24 hours, outperforming other tested agents.
Conclusions:
- SAP beads present a considerable risk to pediatric patients, necessitating prompt management.
- Hyperosmolar agents and osmotic laxatives show promise in reducing SAP bead size, potentially offering a non-surgical treatment option.
Introduction:
Superabsorbent polymer (SAP) bead ingestion poses a challenge for children, sometimes necessitating surgical intervention due to bowel obstruction. We present a literature review and in vitro experiment to explore strategies to contract enlarged SAP beads.
Methods:
A literature review (PubMed, Google Scholar) was also conducted to identify cases of SAP bead-induced bowel obstruction in children. Diagnostic strategies, treatments, and outcomes were abstracted. We then conducted an in vitro experiment where SAP beads were grown in a simulated intestinal environment (normal saline, 37°C) and exposed to potentially therapeutic agents with different osmolarities to explore size reduction mechanisms.
Results:
We identified 87 patients (14.0 ± 4.5 mo) from 45 studies with bowel obstruction following SAP bead ingestion. Abdominal radiograph (73.5%) visualized the SAP bead in 5.6% of instances, whereas ultrasound (57.1%) identified the SAP bead in 85.7% of instances. 85.6% of patients required enterotomy (71.4%). Most postoperative complications were reoperations (16.3%) to remove additional beads. One mortality was recorded. In the in vitro experiment, the osmotic laxative GoLYTELY contributed to a 35.17% reduction in the size of expanded SAP beads within 24 h, demonstrating its efficacy alongside hyperosmolar solutions such as Gastrografin, prune juice, and acetylcysteine.
Conclusions:
SAP beads pose significant risk in children. Hyperosmolar agents and osmotic laxatives may present a therapeutic option by reducing bead size, potentially averting the need for surgical intervention in the setting of SAP-induced bowel obstruction.
Related Concept Videos
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Prevention of Further Absorption of Poison
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

